Hjem › Interstitielle lungesykdommer › Michigan
Kliniske studier for Interstitielle lungesykdommer i Michigan
16 studier for Interstitielle lungesykdommer søker deltakere på steder i Michigan.
Byer i Michigan
Offisiell studietekst (engelsk)
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
- University of Michigan, Ann Arbor
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07540988A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
- University of Michigan, Ann Arbor
RekruttererFase 3
Alder 40 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT07201922Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
- Allen Park, Allen Park
RekruttererFase 2
Alder 18 til 80 · Alle kjønn · Oppdatert 8. sep. 2026 · NCT07473700A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, Ann Arbor
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 8. sep. 2026 · NCT05878717A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
- Henry Ford Health, Detroit
RekruttererFase 2
Alder 40 og eldre · Alle kjønn · Oppdatert 4. sep. 2026 · NCT06968845Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
- University of Michigan - Michigan Medicine, Ann Arbor
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 2. sep. 2026 · NCT06911632A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
- Clinical Research Site, Ann Arbor
- Clinical Research Site, Detroit
RekruttererFase 2
Alder 18 til 85 · Alle kjønn · Oppdatert 2. sep. 2026 · NCT07333183DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- Corewell Health Beamont Troy Hospital, Troy
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 26. aug. 2026 · NCT06388421PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
- University of Michigan, Ann Arbor
RekruttererObservasjonsstudie
Alder 18 til 80 · Alle kjønn · Oppdatert 18. aug. 2026 · NCT06855329Platform Clinical Study for Conquering Scleroderma
- University of Michigan, Ann Arbor
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 18. aug. 2026 · NCT06195072RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- University of Michigan, Ann Arbor
RekruttererFase 2/3
Alder 18 til 75 · Alle kjønn · Oppdatert 17. aug. 2026 · NCT06328777Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
- Henry Ford Health, Detroit
RekruttererObservasjonsstudie
Alder 21 og eldre · Alle kjønn · Oppdatert 12. aug. 2026 · NCT01915511A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
- University of Michigan, Ann Arbor
RekruttererFase 2
Alder 18 til 80 · Alle kjønn · Oppdatert 10. aug. 2026 · NCT07175038Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
- Corewell Health Grand Rapids Hospitals - Butterworth, Grand Rapids
- Beaumont Hospital, Royal Oak, Royal Oak
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 13. jul. 2026 · NCT05943535A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
- Galderma Investigational Site # 8743, Ann Arbor
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 31. mar. 2026 · NCT07047690Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease
- University of Michigan, Ann Arbor
RekruttererObservasjonsstudie
Alder 18 til 90 · Alle kjønn · Oppdatert 3. mai 2024 · NCT06397677Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.